Show simple item record

Authordc.contributor.authorVarela Figueroa, Nelson Miguel Edgardo
Authordc.contributor.authorGuevara Ramírez, Patricia
Authordc.contributor.authorAcevedo Castillo, Cristian Andrés
Authordc.contributor.authorZambrano Coloma, Tomas Andres
Authordc.contributor.authorArmendáriz Castillo, Isaac
Authordc.contributor.authorGuerrero, Santiago
Authordc.contributor.authorQuiñones, Luis A.
Authordc.contributor.authorLópez Cortés, Andrés
Cita de ítemdc.identifier.citationFrontiers in Pharmacology April 2021 Volume 12 Article 630658es_ES
Abstractdc.description.abstractBackground: Breast cancer (BRCA) and prostate cancer (PRCA) are the most commonly diagnosed cancer types in Latin American women and men, respectively. Although in recent years large-scale efforts from international consortia have focused on improving precision oncology, a better understanding of genomic features of BRCA and PRCA in developing regions and racial/ethnic minority populations is still required. Methods: To fill in this gap, we performed integrated in silico analyses to elucidate oncogenic variants from BRCA and PRCA driver genes; to calculate their deleteriousness scores and allele frequencies from seven human populations worldwide, including Latinos; and to propose the most effective therapeutic strategies based on precision oncology. Results: We analyzed 339,100 variants belonging to 99 BRCA and 82 PRCA driver genes and identified 18,512 and 15,648 known/predicted oncogenic variants, respectively. Regarding known oncogenic variants, we prioritized the most frequent and deleterious variants of BRCA (n = 230) and PRCA (n = 167) from Latino, African, Ashkenazi Jewish, East Asian, South Asian, European Finnish, and European non-Finnish populations, to incorporate them into pharmacogenomics testing. Lastly, we identified which oncogenic variants may shape the response to anti-cancer therapies, detailing the current status of pharmacogenomics guidelines and clinical trials involved in BRCA and PRCA cancer driver proteins. Conclusion: It is imperative to unify efforts where developing countries might invest in obtaining databases of genomic profiles of their populations, and developed countries might incorporate racial/ethnic minority populations in future clinical trials and cancer researches with the overall objective of fomenting pharmacogenomics in clinical practice and public health policies.es_ES
Patrocinadordc.description.sponsorshipUniversity of Chile Latin American Society of Pharmacogenomics and Personalized Medicine (SOLFAGEM)es_ES
Publisherdc.publisherFrontiers Mediaes_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
Link to Licensedc.rights.uri*
Sourcedc.sourceFrontiers in Pharmacologyes_ES
Keywordsdc.subjectOncogenic variantses_ES
Keywordsdc.subjectLatino populationes_ES
Keywordsdc.subjectPrecision oncologyes_ES
Títulodc.titleA new insight for the identification of oncogenic variants in breast and prostate cancers in diverse human populations, with a focus on latinoses_ES
Document typedc.typeArtículo de revistaes_ES
dc.description.versiondc.description.versionVersión publicada - versión final del editores_ES
dcterms.accessRightsdcterms.accessRightsAcceso abiertoes_ES
Indexationuchile.indexArtículo de publícación WoSes_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States